COMPANY PROFILE

TAI Diagnostics

Explore full profile

Biotechnology company focused on providing a non-invasive and highly sensitive diagnostic test

Wauwatosa, United StatesFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2018

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About TAI Diagnostics

TAI Diagnostics, Inc. is a biotechnology company specializing in non-invasive and highly sensitive diagnostic tests to monitor the health of transplanted organs. The company serves both healthcare providers and patients who have received solid organ transplants. Operating in the transplant surveillance market, TAI Diagnostics leverages cell-free DNA technology to provide accurate and timely health assessments of transplanted organs. Founded in 2015 and headquartered in the Milwaukee County Research Park, the company is strategically located near the Medical College of Wisconsin, Blood Research Institute, and Milwaukee Regional Medical Center. TAI Diagnostics generates revenue by selling its diagnostic tests and related services to healthcare providers, who then use these tests to monitor their transplant patients. The company's business model focuses on continuous innovation and collaboration with medical institutions to improve transplant outcomes and patient care.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Wauwatosa, United States
Employees: 10
Open positions: None listed
Dealroom signal: 54.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Non-Invasive medical devices and treatments, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jan 2018	$10M	$40M	Venture Investors Health Fund	—
DEBT✓Debt	Jan 2017	$1.8M	—	Venture Investors Health Fund	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

TAI Diagnostics website traffic

Latest recorded traffic for TAI Diagnostics is 230 monthly website visits, up 109.1% over the last three months. TAI Diagnostics's team grew 0% over the past year.

Latest monthly visits230 3-month web change+109.1% 1-year team growth0%

Monthly website visitsOct 2017–Jun 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STSinaptica TherapeuticsClinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease	Cambridge, United States	Operational	19	—	—
BIBioSenicFor autoimmune, inflammatory and bone diseases	Mont-Saint-Guibert, Belgium	Operational
GEGelmetixInjectable polymer gel for non-surgical chronic pain treatment	London, United Kingdom	Operational
DXDxCoverDeveloping a spectroscopic liquid biopsy for rapid detection of cancer	Glasgow, United Kingdom	Operational
KYKYLYSPeople and patients with highly effective and safe products based on biomolecules	Geneva, Switzerland	Operational
VOxford VacmedixDevelop therapeutic agents for the treatment of cancer	Oxford, United Kingdom	Operational
SCScribensDevelopment of non-invasive tools for early detection and follow-up of neurological dysfunctions	Montreal, Canada	Closed
CRCroivalveTreating Heart Valve Disease	Dublin, Ireland	Operational